logo

For the Inventor, By the Inventor

Washington, DC, United States of America

Vanda Pharmaceuticals Inc.


USPTO Granted Patents = 117



Trademarks = 19

Forward Citations = 358

Loading Chart...
Loading Chart...

46 inventors (with patents filed for the assignee):

goldMedal Mihael Hristos Polymeropoulos (79 out of 85 patents)

silverMedal Louis William Licamele (45 out of 45 patents)

bronzeMedal Marlene Michelle Dressman (30 out of 30 patents)

4.  Christian Lavedan (28 out of 28 patents)

5.  Deepak Phadke (18 out of 19 patents)

6.  John Joseph Feeney (15 out of 16 patents)

7.  Simona Volpi (15 out of 15 patents)

8.  Curt Douglas Wolfgang (14 out of 18 patents)

9.  Paolo Baroldi (9 out of 9 patents)

10.  Sandra Smieszek (8 out of 8 patents)

11.  Natalie M Platt (8 out of 8 patents)

12.  Ravi K Pandrapragada (8 out of 8 patents)

13.  Gunther Birznieks (6 out of 6 patents)

14.  Kendra Tomino Mack (3 out of 3 patents)

15.  Callie Michelle Heaton (3 out of 3 patents)


Core Competencies:
Cancer Treatment
Schizophrenia
Circadian Rhythm Disorders
Tasimelteon
Tradipitant
Multiple Sclerosis
Cognitive Enhancement
Pharmaceutical Combinations
Dosing Regimen
Genetic Markers
Fatigue-Related Symptoms
Atopic Dermatitis

117 patents:

1. 12760367 - Treatment of atopic dermatitis with tradipitant (2026-10-13),
2. 12728116 - Methods of treating multiple sclerosis (2026-09-08),
3. 12673055 - Treatment of atopic dermatitis with tradipitant (2026-07-07),
4. 12673033 - Multiple myeloma treatment (2026-07-07),
5. 12622915 - Methods of treating PDE IV-mediated diseases or conditions (2026-05-12),
6. 12590162 - Cancer treatment (2026-03-31),
7. 12582640 - Treatment of lower respiratory tract infection with tradipitant (2026-03-24),
8. 12544367 - Method of treatment of schizophrenia (2026-02-10),
9. 12527772 - Pharmaceutical combination comprising ponesimod (2026-01-20),
10. 12502379 - Ponesimod for avoiding worsening of fatigue-related symptoms in multiple sclerosis patients (2025-12-23),
11. 12478619 - Method of treatment with milsaperidone (2025-11-25),
12. 12447141 - Liquid tasimelteon formulations and methods of use thereof (2025-10-21),
13. 12440470 - Liquid tasimelteon formulations and methods of use thereof (2025-10-14),
14. 12427132 - Method of improving sleep (2025-09-30),
15. 12419869 - Methods of treating multiple sclerosis (2025-09-23),
Company Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company based in Washington, DC, specializing in the development of innovative treatments for various medical conditions. The company focuses on therapeutic areas including cancer treatment, schizophrenia, and circadian rhythm disorders. Notable products include Tasimelteon, aimed at addressing sleep disorders, and Tradipitant, which targets multiple sclerosis and cognitive enhancement. Vanda's commitment to advancing pharmaceutical combinations underscores its dedication to improving patient outcomes through targeted therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Vanda Pharmaceuticals Inc. USPTO Patent Assignee Logo
117 Patents

#19 in Washington, DC

#19 in District of Columbia

#3,297 in US

#6,800 in the World

Washington, DC (US)
Washington, DC, United States of America

Vanda Pharmaceuticals Inc.

Forward Citations = 358

46 inventors:

goldMedal Mihael Hristos Polymeropoulos (79 out of 85 patents)

silverMedal Louis William Licamele (45 out of 45 patents)

bronzeMedal Marlene Michelle Dressman (30 out of 30 patents)

4.  Christian Lavedan (28 out of 28 patents)

5.  Deepak Phadke (18 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vanda Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/vanda-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…